Gene variants, insulin resistance, and dyslipidaemia

Current Opinion in Lipidology

Volumn 15, Issue 2, 2004, Pages 115-120

  Laakso, Markku ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Dyslipidaemia; Hepatic lipase; Insulin receptor substrate; Insulin sensitivity; LDL size; PC 1; PPAR 2

Indexed keywords

FATTY ACID BINDING PROTEIN; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; MEMBRANE PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROTEIN PC 1; UNCLASSIFIED DRUG;

ALLELE; DNA POLYMORPHISM; DYSLIPIDEMIA; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC LINKAGE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLUCOSE METABOLISM; HEREDITY; HORMONE ACTION; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOPROTEIN METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW;

ALLELES; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; PHOSPHORIC DIESTER HYDROLASES; PPAR GAMMA; PYROPHOSPHATASES; RISK FACTORS; VARIATION (GENETICS);

EID: 1842452946     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200404000-00004     Document Type: Review

References (37)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
2. Rhodes CJ, White MF. Molecular insights into insulin action and secretion. Eur J Clin Invest 2002; 32 (Suppl. 3):3-13.
3. Haffner SM, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003; 108:1541-1545.
4. Reilly MP, Rader DJ. The metabolic syndrome. More than the sum of its parts? Circulation 2003; 108:1546-1551. This study reviews the past and current definition of the metabolic syndrome.
5. Lempiäinen P, Mykkänen L, Pyörälä K, et al. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999; 100:123-128.
6. Lehto S, Rönnemaa T, Pyörälä K, Laakao M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type II diabetes. Diabetologia 2000; 43:148-155.
7. Bergman RN, Zaccaro D, Watanabe RM, et al. Minimal model-based insulin sensitivity has greater heritability and a different genetic basis than homeostasis model assessment or fasting insulin. Diabetes 2003; 52:2168-2174. An excellent study comparing estimates based on fasting insulin, the HOMA index, and the insulin sensitivity index evaluated by the minimal model in a large number of subjects from the insulin Resistance and Atherosclerosis Study.
8. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 2000; 7:325-331.
9. Frititta L, Baratta R, Spampinato D, et al. The Q121K PC-1 variant and obesity have additive and independent effects in causing insulin resistance. J Clin Endocrinol Metab 2001; 86:5888-5891.
10. Kubaszek A, Pihlajamäki J, Karhapää P, et al. The K121Q polymorphism of the PC-1 gene is associated with insulin resistance but not with dyslipidemia. Diabetes Care 2003; 26:464-467. This study gives evidence that the effects of PC-1 on insulin action are probably present only in skeletal muscle.
11. Gonzales Sanchez JL, Serrano Rios M, Fernandez Perez C, et al. Effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol 2002; 147:495-501.
12. Almind K, Inoue G, Pedersen O, Kahn CR. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest 1996; 97:2569-2575.
13. Marini MA, Frontoni S, Mineo D, et al. The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patient. J Clin Endocrinol Metab 2003; 88:3368-3371. A comprehensive study on the significance of the common variant in the IRS-1 gene on glucose metabolism, lipids and lipoproteins, and markers of early atherosclerosis.
14. Baroni MG, Arca M, Sentinelli F, et al. The G972R variant of the insulin receptor substrate-1 (IRS-1) gene, body fat distribution and insulin resistance. Diabetologia 2001; 44:367-372.
15. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002; 283:E413-E422. An excellent review on the early insulin signalling pathway.
16. Wang H, Rissanen J, Miettinen R, et al. New amino acid substitutions in the IRS-2 gene in Finnish and Chinese subjects with late-onset type 2 diabetes. Diabetes 2001; 50:1949-1951.
17. D'Alfonso R, Marini MA, Frittitta L, et al. Polymorphisms of the insulin receptor substrate-2 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88:317-322. This in-vivo and in-vitro study indicates that the common variant (Gly1057Asp) of the IRS-2 gene does not associate with insulin resistance, insulin secretion, or IRS-2 function in fibroblasts from carriers of this polymorphism. No defect in IRS-2 expression, insulin-stimulated phosphorylation, or binding to the p85 subunit of phosphatidylinositol 3-kinase was found.
18. Gurnell M, Savage DB, Chatterjee KK, O'Rahilly S. The metabolic syndrome: peroxisome proliferator-activated receptor γ and its therapeutic modulation. J Clin Endocrinol Metab 2003; 88:2412-2421. A comprehensive review on nuclear receptors (PPAR), their association with the metabolic syndrome and their therapeutic modulation.
19. Camejo G. PPAR agonists in the treatment of insulin resistance and associated arterial disease. Int J Clin Pract (Suppl.) 2003; 134:36-44.
20. Lee C-H, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003; 144:2201-2207. A review on the effects of peroxisome proliferator-activated receptors PPAR-α, PPAR-γ, and PPAR-δ, on glucose and lipid metabolism. Therapeutic aspects are also discussed.
21. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20:284-287.
22. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26:76-80.
23. Lindi VI, Uusitupa MI, Lindströn J, et al. for the Finnish Diabetes Prevention Study Group. Association of ths Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 2002; 51:2581-2586. The Finnish Diabetes Prevention Study showed that the Pro12Ala polymorphism has a very strong interaction with life-style changes, implying a crucial role of the gene-environment interaction in the risk of type 2 diabetes.
24. Eriksson J, Lindi V, Uusitupa M, et al. The effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene on insulin sensitivity and insulin metabolism interact with size at birth. Diabetes 2002; 51:2321-2324.
25. Eriksson J, Lindi V, Uusitupa M, et al. The effects of the Pro12Ala polymorphism of the PPAR-gamma2 gene on lipid metabolism interact with body size at birth. Clin Genet 2003; 64:366-370. This study showed that the 12Ala allele was associated with lipid and lipoprotein levels only among those who had a low birthweight.
26. Baratta R, Di Paola R, Spampinato D, et al. Evidence for genetic epistasis in human insulin resistance: the combined effect of PC-1 (K121Q) and PPARgamma2 (P12A) polymorphisms. J Mol Med 2003; 81(11):718-23. This original study demonstrates a gene-gene interaction with respect to common polymorphisms in the PC-1 and PPAR-γ2 genes.
27. Lambert G, Amar MJ, Martin P, et al. Hepatic lipase deficiency decreases the selective uptake of HDL-cholesteryl esters in vivo. J Lipid Res 2000; 41:667-672.
28. Ordovas JM, Corella D, Demissie S, et al. Dietary fat intake determines the effect of a common polymorphism in the hepatic lipase gene promoter on high-density lipoprotein metabolism. Evidence of a strong dose effect in this gene-nutrient interaction in the Framingham Study. Circulation 2002; 106:2315-2321. A very important study demonstrating a gene-nutrient interaction with respect to a variant in the promoter region of the hepatic lipase gene.
29. Weiss EP, Brown MD, Shuldiner AR, Hagberg JM. Fatty acid binding protein-2 gene variants and insulin resistance: gene and gene-environment interaction effects. Physiol Genom 2002; 10:145-157. A comprehensive review particularly on the Ala54Thr polymorphism of the fatty acid binding protein 2 gene. The review concentrates particularly on the interaction between behavioural and environmental factors and the Ala54Thr polymorphism.
30. Baier LJ, Sacchettini JC, Knowler WC, et al. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J Clin Invest 1995; 95:1281-1287.
31. Galluzzi JR, Cupples LA, Meigs JB, et al. Association of the Ala54Thr polymorphism in the intestinal fatty acid-binding protein with 2-h post-challenge insulin levels in the Framingham Offspring Study. Diabetes Care 2001; 24:1161-1166.
32. Ågren JJ, Valve R, Vidgren H, et al. Postprandial lipemic response is modified by the polymorphism at codon 54 of the fatty acid-binding protein 2 gene. Arterioscler Thromb Vasc Biol 1998; 18:1606-1610.
33. Austin MA, Mykkänen L, Kuusisto J, et al. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 1995; 92:1770-1778.
34. Skoglund-Andersson C, Ehrenborg E, Fischer RM, et al. Influence of common variants in the CETP, LPL, HL and Apo E genes on LDL heterogeneity in healtry, middle-aged men. Atherosclerosis 2003; 167:311-317. LDL particle size is a genetically influenced trait. This original article gives important information about the role of several gene variants in the regulation of LDL heterogeneity.
35. Maclean PS, Tanner CJ, Houmard JA, Barakat HA. Plasma cholesteryl ester transfer protein activity is not linked to insulin sensitivity. Metabolism 2001; 50:783-788.
36. Heilbronn LK, Noakes M, Clifton PM. Association between HDL-cholesterol and the Taq1B polymorphism in the cholesterol ester transfer protein gene in obese women. Atherosclerosis 2002; 162:419-424.
37. Pihlajamäki J, Karjalainen L, Karhapää P, et al. G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2000; 20:1789-1795.